{Reference Type}: Case Reports
{Title}: Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report.
{Author}: Deng S;Yang X;He L;Zhang Q;Zhao C;Meng H;
{Journal}: J Cardiothorac Surg
{Volume}: 19
{Issue}: 1
{Year}: 2024 Apr 9
{Factor}: 1.522
{DOI}: 10.1186/s13019-024-02752-5
{Abstract}: <B>BACKGROUND: </B>Primary cardiac angiosarcoma(PCA) has a low incidence rate and poor prognosis. Currently, no unified clinical treatment standards are available.<BR><B>METHODS: </B>We report the case of a 48-year-old man presenting chest tightness, breathlessness, and dyspnea. Imaging and postoperative histopathologic studies confirmed PCA and that the tumor had invaded the entire right atrium. The patient developed progressive disease (PD) during postoperative radiotherapy. We used immunotherapy combined with targeted therapy based on the results of molecular profile and evaluation of tertiary lymphoid structures (TLSs) and programmed cell death-ligand 1 (PD-L1). After treatment, the metastatic lymph nodes of the patient were reduced to a certain extent, indicating that combination therapy was effective.<BR><B>CONCLUSIONS: </B>To the best of our knowledge, this is the first report of radiotherapy combined with anti-PD-1 and tyrosine kinase inhibitors(TKI) for PCA. In addition, this is the first report on immunotherapy for PCA based on new evaluation methods, including TLSs, PD-L1, and genomic profile.